ABSTRACT
INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a common disorder, affecting 3-6% of schoolage children. 1 Children with ADHD have manifesttations of continuous traits, including hyperactivity, impulsivity, and dysfunction in executive skills. [2] [3] [4] [5] [6] [7] It has been viewed as DNA variants contribute to its complex etiology. [8] [9] [10] Extant evidence indicates that dysregulation of the neurotransmitter systems may be involved in its pathophysiology. 11, 12 Dysregulated expression of glutamatergic pathway genes has been observed in spontaneously hypertensive rat models. 13, 14 Increased concentrations of glutamate were also reported in the neurometabolism of ADHD brains. 15 Glutamatergic neurotransmission is involved in many basic neuronal functions including fast synaptic transmission, neuronal migration, proliferation and excitability. 16 Altered glutamatergic neurotransmission has been implicated in many different CNS processes, physiological and pathological. 17 Genes encoding glutamate receptors represent candidate genes of interest for neuropsychiatric disorders. 18 There are two classes of glutamate receptor. Ionotropic receptors are further classified into N-methyl D-aspartate receptors (NMDA), alpha-amino-3, hydroxy-5-methyl-4-isoxazole propionate receptors (AMPA), kainate (KA) and delta receptors. 16 The metabotropic glutamate receptors (mGluRs) are divided into 3 groups. 14, 19 The mGluRs (GRM) in group I are mGluR1 and mGluR5, those in group II are mGluR2 and mGluR3, and those in group III are mGluRs 4, 6, 7, and 8. 20 The mGluR7 is the most highly conserved mGluR subtype across mammalian species. 21 The mGluR7 is thought to be a key player in shaping synaptic responses at glutamatergic synapses as well as in regulating key aspects of inhibitory GABAergic transmission. 22, 23 The mGluR7 has putative roles in anxiety, emotional responses, and spatial working memory. [24] [25] [26] [27] Neale et al. 28 reported that more than 20 single nucleotide polymorphism (SNP)s of GRM7 showed association with ADHD in the meta-analysis. A genome-wide association study examining the methylphenidate response in children with ADHD found an association with an SNP in GRM7 gene (rs3792452). 29 The above-mentioned evidence suggests that GRM7 represent candidate genes for ADHD or certain phenotypes of ADHD.
Psychostimulants, particularly methylphenidate (MPH), are the most commonly prescribed pharmacological drugs for ADHD. MPH is generally effective not only in reducing symptoms but also in relieving neuropsychological problems such as time variability. [30] [31] [32] We selected this glutamate gene because of its historical prevalence in the literature examining glutamate genes in relation to ADHD. Comparatively fewer studies have investigated the effect of glutamatergic gene polymorphisms on treatment response to MPH. Ohtsuki et al. 20 reported rs 3749380 of GRM7 were associated with schizophrenia. The T allele of GRM7 rs3749380, which is associated with schizophrenia, has lower promoter activity than the C allele. 20 But no published studies have investigated the relationship between the GRM7 rs3749380 polymorphism genotypes and the treatment response to MPH in ADHD subjects. Therefore, the purpose of this study was to evaluate the association between the GRM7 rs3749380 polymorphism genotypes and treatment responses to MPH in Korean children with ADHD.
METHODS

Subjects
Ninety-two drug-naïve ADHD children were enrolled and this study included 86 children with ADHD, as diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text-Revised (DSM-IV-TR) criteria. 33 The children selected for the ADHD group were those who: (1) were 6-12 years old; (2) agreed with informed consent; (3) were diagnosed as having ADHD; (4) had more than 25 points of the pretreatment ADHD Rating Scale (ARS) ; (5) had an IQ score above 80; (6) had no history of exposure to antipsychotic medication. Six children who: (1) had a past history or were currently suffering from medical diseases; (2) had pervasive developmental disorder or mental retardation; (3) had any other psychiatric disorder needed to be treated, were excluded. The study was approved by the institutional review board for human subjects at hospital.
_____________________________________________________________________________________________________
MPH administration and procedures
All of the subjects were drug-naïve at the time of recruitment, and were administered methylphenidate for a total of eight weeks. We started the methylphenidate doses according to their weights. The dosages were increased until sufficient therapeutic effect upon Clinical Global Improvement (CGI) score was reached. Clinical assessment was conducted by certified child and adolescent psychiatrists.
Clinical assessments
Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL):
34 K-SADS-PL was performed for the diagnosis of ADHD. It is a semi-structured interview tool, designed to evaluate the severities of ADHD symptoms and to evaluate the 32 different psychiatric disorders included in DSM-IV. The Korean version of K-SADS-PL (K-SADS-PL-K) was translated, and its validity and reliability of ADHD, tic disorder and oppositional defiant disorder were proven by Kim et al. 34 The Attention-Deficit Hyperactivity Disorder Rating Scale (ARS): The Korean version of the ADHD Rating Scale (ARS) was used for the evaluation of symptoms of ADHD, consisting of a total of 18 items. Each item is scored on a 4-point scale. The scale includes nine items for inattention and nine items related to hyperactivity and impulsivity.
Clinical Global Impression (CGI):
CGI is rated by the clinician and uses measure of symptom severity, treatment response and the efficacy of treatments in most clinical studies with mental disorders. The scale was composed of two subscales, both of which are seven-point scales, that rate symptom severity (CGI-S) and symptom improvement (CGI-I). Scoring on the CGI-I is as follow: (1) very much improved; (2) much improved; (3) minimally improved; (4) no change; (5) minimally worse; (6) much worse; (7) very much worse. CGI-S is as follow: (1) normal; not at all ill; (2) borderline mentally ill; (3) mildly ill; (4) moderately ill; (5) markedly ill; (6) severely ill; or (7) extremely ill.
Neuropsychological assessments
The Continuous Performance Test (CPT):
Attention and response inhibition were assessed using a standardized visual and auditory form of the Korean version of the computerized Continuous Performance Test (CPT).
The four variables that were recorded were (1) omission errors, which are commonly interpreted as a measure of inattention; (2) commission errors, which are interpreted as a measure of impulsivity; (3) response times for correct responses to the target, which are interpreted as a measure of information processing and motor response speed; and (4) response time variability, which is interpreted as a measure of variability or consistency of attention.
Treatment response
A response criterion was defined based on the CGI-I, CGI-S, and the ARS score at baseline and three weeks after MPH treatment. 35 The dichotomous response criterion, 'good' responder vs. 'poor' responder, was applied. First criterion, based on a change of ARS total score, 'good' responder had an improvement of ≥50% compared with the baseline ARS score. Second criterion was defined by CGI-I score, 'good' responder who had 1 or 2 points after MPH treatment, whereas a 'poor' responder had a CGI-I score in the range of 3-7 points. 36 Third criterion defined by CGI-S score after MPH treatment, a 'good' responder had a 1 or 2 score and 3 to 7 score as a 'poor' responder. Fourth criterion, a 'good' responder had satisfied of all aforementioned criteria.
Genotyping
The genotyping was screened using single base primer extension assay using ABI PRISM SNaPshot Multiplex kit (ABI, Foster City, CA, USA) according to manufacturer's recommenddation.
The genomic DNA flanking the interested SNP was amplified with PCR reaction with 5'-CGT CCT GAC TTT GAT GAA G and 5'-AAA GTA AGC GAC TGT TCG AG for the GRM7 polymorphism (rs3749380) and standard PCR reagents in 10 microliter reaction volume, containing 10ng of genomic DNA, 0.5pM of each oligonucleotide primer, 1microliter of 10X PCR buffer, 250mM dNTP (2.5mM each) and 0.25 unit i-StarTaq DNA Polymerase (5unit/μl) (iNtRON Biotechnology, Sungnam, Kyungki-Do, Korea).
Statistical analyses
The allele frequencies were estimated by counting, and the Hardy-Weinberg equilibrium was calculated based on these allele frequencies, using χ 2 (chi-square) test. Group differences in the clinical variables involving continuous data were summarized using median (minimum, maximum) and tested by a Kruskall-Wallis test rather than parametric method because of small size of data. Between-group comparisons involving categorical data were assessed using a Fisher's exact test. For assessing treatment outcome, Kruskall-Wallis test was used for analyzing effects of MPH treatment and polymorphism. The Dunn's method was applied for pair-wise multiple comparisons for significant outcomes from Kruskall-Wallis tests. It controls inflation of type I error due to multiple comparisons. Dependant variables included ARS and CPT score and the fixed factors were genes. All tests were two-tailed and significance was defined as an alpha <0.05.
RESULTS
Our sample consisted of 86 children with ADHD including 74 boys and 12 girls. Of the DSM-IV subtypes of ADHD, the hyperactive impulsive subtype was the most common in our subjects, followed by combined and the inattentive subtype. 
_____________________________________________________________________________________________________
Genotype analysis of the GRM7 rs3749380 polymorphism identified the C/C genotype in 55 subjects, the C/T genotype in 28 subjects, and the T/T genotype in three subjects. The C allele of the GRM7 rs3749380 polymorphism was identified in 138/172 chromosomes and the T allele was identified in 34/192 chromosomes.
After eight weeks of treatment, the total ARS score decreased, from 33 at baseline to 18 in C/C genotype, from 30.5 at baseline to 13 in C/T genotype and from 34 at baseline to 13 in T/T genotype, indicating an improvement in symptoms.
No statistically significant differences in age, weight, ADHD subtype, and sex were observed among genotypic groups.
There was no significant effect of the GRM7 rs3749380 polymorphisms and on ARS scores. However, we observed statistically significant differences in visual response times (p=0.017), response time variability (p=0.029) and auditory response times (p=0.007) on CPT depending on genotypes (Table 2 ).
Dunn's nonparametric comparison for post-hoc test revealed that with respect to visual response times, TT genotype was significant different from CT (p=0.014) and CC (p=0.02). With respect to visual response time variability, TT genotype was statistically different from CT (p=0.032) and CC (p=0.025). And with respect to auditory response time, TT genotype was significant different from CC (p=0.02) ( Table 3 ).
In comparing distributions of ARS, CPT between GRM7 rs3749380 polymorphism after MPH treatment, Kruskall-Wallis test was performed. There was no significant effect of the GRM7 rs3749380 polymorphisms on ARS scores. However, we observed statistically significant differences in visual omission errors (p=0.0123), auditory omission errors (p=0.0325) and commission errors (p=0.0336) on CPT ( Table 2 ).
The post-hoc test using Dunn's method revealed that with respect to visual omission errors, TT genotype was significant different from CT (p=0.01) and CC (p=0.034). With respect to auditory omission errors, TT genotype was significant different from CT (p=0.028) and CC (p=0.036). And with respect to auditory commission errors, TT genotype was significant different from CT (p=0.029) and CC (p=0.038) ( Table 3) . After eight weeks of treatment with MPH, the MPH treatment response according to the GRM7 rs3749380 polymorphism genotype was examined. No significant differences were found between the treatment improvement and ARS scores according to the GRM7 rs3749380 polymorphism. However, we found significant difference between the T/T genotype and response in terms of visual response times and auditory commission errors on the CPT compared with the other genotypes (Table 4 ).
Dunn's test revealed that with respect to visual response times, TT genotype was marginally significantly different from CT (p=0.052) and significantly different from CC (p=0.046). And with respect to auditory commission errors, TT genotype was significantly different from CT (p=0.034) ( Table 5) .
DISCUSSION
To the best of our knowledge, this is the first study to examine the associations between the GRM7 rs3749380 polymorphism genotypes and In this study, total ARS scores were also indifferent between the groups at baseline as showed in Table 2 . No significant association was found between the GRM7 rs3749380 genotype and treatment response measured by total ARS and this result suggested that the GRM7 rs3749380 interaction may have a limited impact on the effect of MPH on ADHD symptoms in particular. Our small sample size may have reduced the likelihood of finding statistical significance.
But there was a significant effect on several variables in CPT performance. At baseline, we found that homozygous subjects for the T allele (T/T genotype) were significantly different on the CPT visual and auditory response times and visual response time variability as compared with those with the C/C or C/T genotypes. After 8-week MPH treatment, subjects with the T/T genotype were different in visual and auditory omission errors and commission errors on CPT.
With regard to the assessment of treatment response to MPH using objective neuropsychological measures, the ADHD subjects with more copies of the T allele of GRM7 gene (rs3749380) polymorphism showed more reduction in visual response times, but more increase in auditory commission errors on the CPT. These results showed somewhat differences with other previous studies, 20, 37, 38 which identified the T allele as a putative risk allele of the GRM7 gene (rs3749380) polymorphism. Those studies reported an association between the T allele of the _____________________________________________________________________________________________________ of the GRM7 rs3749380 polymorphism and schizophrenia symptoms. 20, 37, 38 We can infer that possessing the risk (T) allele of this polymorphism may contribute to a greater improvement in some profiles in neuropsychological performance after MPH treatment in subjects with ADHD, but not in others. These result suggested that MPH may have a limited impact on some ADHD symptoms in particular. Our short treatment time may cause poor treatment effects. In this study, it also might be noted that the association between the GRM 7 genotypes and baseline clinical characteristics such as symptom severity may influence these pharmacogenetic findings because higher baseline severity has been reported to predict a greater treatment response in ADHD subjects. 39, 40 Buitelaar et al. 39 suggested that there may be a greater potential for improvement in more severe compared with less severe patients.
In summary, results of the present study were T/T genotype group showed significant difference on the CPT measure of visual response times and auditory commission errors compared with C/T or C/C genotype group. These have been proposed as a putative endophenotype with the potential to index genetic variability in ADHD. 41 Our data provide further support for the candidacy of response times and commission errors as an endophenotype for ADHD and suggest that variations in this phenotype are related to genetic variations in the GRM 7 gene.
Several limitations of this study should be noted. First, this study has no placebo controlled group and open-label design. Second, we did not compare the GRM7 rs3749380 polymorphisms in subjects with ADHD with those in healthy controls. Third, our study assessed short-term outcomes, which are incomplete assessments of treatment response. Long-term outcomes might prove to be much more clinically relevant for investigation. Fourth, we did not stratify our results according to DSM-IV subtypes and thus cannot comment upon whether our effects are driven by a particular dimension. And another possible limitation is that candidate genes in our study are not a major gene on ADHD genetic study. Finally, due to small sample size of our study, it must be required for replication with large sample size. Thus, the results should be interpreted cautiously.
